Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Continuous subcutaneous insulin infusion with portable pumps].

R P Radermecker1, M P Hermans, D A Legrand

  • 1Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine, CHU Sart Tilman. Regis.Radermecker@ulg.ac.be

Revue Medicale De Liege
|July 23, 2005
PubMed
Summary

Continuous subcutaneous insulin infusion (CSII) offers superior glucose control for type 1 diabetes compared to injections. This advanced therapy requires careful patient selection and multidisciplinary management for optimal results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007

Area of Science:

  • Endocrinology and Metabolism
  • Diabetology

Context:

  • Type 1 diabetes mellitus necessitates exogenous insulin for glycemic control.
  • Achieving normoglycemia is crucial to prevent long-term complications while minimizing hypoglycemia risk.

Purpose:

  • To outline recommendations, advantages, limitations, and costs of continuous subcutaneous insulin infusion (CSII) using portable pumps for type 1 diabetes patients.
  • To compare CSII with conventional multiple injection insulin therapy.

Summary:

  • CSII with portable pumps is the most advanced insulin delivery method, closely mimicking physiological insulin secretion.
  • This therapy demonstrates improved glucose control and stability over multiple daily injections.
  • Effective CSII implementation requires adherence to specific indications and structured management by a multidisciplinary team.

Related Experiment Videos

Impact:

  • CSII represents a significant advancement in insulin delivery for type 1 diabetes.
  • Optimized glycemic control via CSII can help prevent or delay chronic diabetic complications.
  • Structured management protocols are essential for maximizing the benefits of CSII therapy.